Moreover, the epigenetic induction of CD1d in tumors has been suggested as a mechanism to sensitize lung cancer to iNKT treatment [6], and thymosin alpha1, which is widely used as an immune adjuvant to cancer therapy, was observed to enhance the cytotoxicity of iNKT cells against colon cancer via upregulating CD1d expression [7]. Here, CD1D is linked to malignant colon neoplasm.